Movement Disorders (revue) - Exploration (Accueil)

Index « Keywords » - entrée « Receptors, Dopamine D2 (drug effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Receptors, Dopamine D2 (analysis) < Receptors, Dopamine D2 (drug effects) < Receptors, Dopamine D2 (genetics)  Facettes :

List of bibliographic references indexed by Receptors, Dopamine D2 (drug effects)

Number of relevant bibliographic references: 19.
Ident.Authors (with country if any)Title
002007 (2009) Livia Brusa [Italie] ; Antonio Orlacchio [Italie] ; Vincenzo Moschella [Italie] ; Cesare Iani [Italie] ; Giorgio Bernardi [Italie] ; Nicola Biagio Mercuri [Italie]Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
002763 (2008) Paolo Calabresi [Italie] ; Massimiliano Di Filippo [Italie] ; Veronica Ghiglieri [Italie] ; Barbara Picconi [Italie]Molecular mechanisms underlying levodopa‐induced dyskinesia
002999 (2008) Virginie Czernecki [France] ; Michael Schüpbach [France, Suisse] ; Sadek Yaici [France] ; Richard Lévy [France] ; Eric Bardinet [France] ; Jérôme Yelnik [France] ; Bruno Dubois [France] ; Yves Agid [France]Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom
003D37 (2004) Ida Rissling [Allemagne] ; Frank Geller [Allemagne] ; Oliver Bandmann [Allemagne] ; Karim Stiasny-Kolster [Allemagne] ; Yvonne Körner [Allemagne] ; Charlotte Meindorfner [Allemagne] ; Hans-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; J. Carsten Möller [Allemagne]Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting “sleep attacks”
004A78 (2000) Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Endogenous dopaminergic tone and dopamine agonist action
004C17 (1999) Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France]Treatment of Parkinson's disease should begin with a dopamine agonist
004C34 (1999) Christine Dentresangle [France] ; Laurent Veyre [France] ; Didier Le Bars [France] ; Christian Pierre [France] ; Frank Lavenne [France] ; Pierre Pollak [France] ; Jeanine Guerin [France] ; Jean-Claude Froment [France] ; Emmanuel Brousolle [France]Striatal D2 dopamine receptor status in Parkinson's disease: An [18F]dopa and [11C]Raclopride PET study
005213 (1997) Schwarz [Allemagne] ; K. Tatsch [Allemagne] ; T. Gasser [Allemagne] ; G. Arnold [Allemagne] ; Oertel [Allemagne][123]IBZM Binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy
005308 (1997) G. Dziewczapolski [Argentine] ; L. B. Menalled [Argentine] ; M. T. Savino [Argentine] ; M. Mora [Argentine] ; F. J. E. Stefano [Argentine] ; Gershanik [Argentine]Mechanism of action of clozapine‐induced modification of motor behavior in an animal model of the “super‐off” phenomenon
005319 (1997) Angelo Antonini [Suisse] ; Johannes Schwarz [Suisse] ; Wolfgang H. Oertel [Suisse] ; Oliver Pogarell [Suisse] ; Leenders [Suisse, Allemagne]Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride
005594 (1996) Picard [France] ; A. De Saint-Martin [France] ; E. Salmon [Belgique] ; E. Hirsch [France] ; C. Marescaux [France]Postencephalitic stereotyped involuntary movements responsive to L‐Dopa
005633 (1996) Jauss [Allemagne] ; P. Krack [Allemagne] ; M. Franz [Allemagne] ; R. Klett [Allemagne] ; R. Bauer [Allemagne] ; B. Gallhofer [Allemagne] ; W. Dorndorf [Allemagne]Imaging of dopamine receptors with [123I]iodobenzamide single‐photon emission–computed tomography in neuroleptic malignant syndrome
005686 (1996) Geminiani [Italie] ; Vincenza Fetoni [Italie] ; Silvia Genitrini [Italie] ; Paolo Giovannini [Italie] ; Filippo Tamma [Italie] ; Tommaso Caraceni [Italie]Cabergoline in Parkinson's disease complicated by motor fluctuations
005710 (1996) Lance Smith [Royaume-Uni] ; Maria De Salvia [Royaume-Uni] ; Jenner [Royaume-Uni] ; C. David Marsden [Royaume-Uni]An appraisal of the antiparkinsonian activity of piribedil in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets
005A77 (1994) Trugman [États-Unis] ; Robert Leadbetter [États-Unis] ; Michael E. Zalis [États-Unis] ; Rose O. Burgdorf [États-Unis] ; G. Frederick Wooten [États-Unis]Treatment of severe axial tardive dystonia with clozapine: Case report and hypothesis
005A84 (1994) R. J. Vermeulen [Pays-Bas] ; Drukarch [Pays-Bas] ; M. C. R. Sahadat [Pays-Bas] ; C. Goosen [Pays-Bas] ; E. C. Wolters [Pays-Bas] ; J. C. Stoof [Pays-Bas]The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐lesioned parkinsonian rhesus monkeys
005A88 (1994) Mendis [Canada] ; Erich Mohr [Canada] ; Amanda George [Canada] ; Ilene N. Rusk [Canada] ; Peggy Gray [Canada] ; J. David Grimes [Canada]Symptomatic relief from treatment‐induced psychosis in Parkinson's disease: An open‐label pilot study with remoxipride
005B26 (1994) Belluzzi [États-Unis] ; E. F. Domino [États-Unis] ; J. M. May [États-Unis] ; K. S. Bankiewicz [États-Unis] ; D. A. Mcafee [États-Unis]N‐0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease
005D92 (1993) Kostic [Serbie] ; Zorica Marinkovic [Serbie] ; Sasa Filipovic [Serbie] ; Dragana Momcilovic [Serbie]Function of dopamine receptors in young‐onset parkinson's disease: Prolactin response

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Receptors, Dopamine D2 (drug effects)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Receptors, Dopamine D2 (drug effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Receptors, Dopamine D2 (drug effects)
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024